title: Radical prostatectomy or watchful waiting in early prostate cancer.
abstract: BACKGROUND
  Radical prostatectomy reduces mortality among men with localized prostate cancer; however, important questions regarding long-term benefit remain.
  
  
  METHODS
  Between 1989 and 1999, we randomly assigned 695 men with early prostate cancer to watchful waiting or radical prostatectomy and followed them through the end of 2012. The primary end points in the Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) were death from any cause, death from prostate cancer, and the risk of metastases. Secondary end points included the initiation of androgen-deprivation therapy.
  
  
  RESULTS
  During 23.2 years of follow-up, 200 of 347 men in the surgery group and 247 of the 348 men in the watchful-waiting group died. Of the deaths, 63 in the surgery group and 99 in the watchful-waiting group were due to prostate cancer; the relative risk was 0.56 (95% confidence interval [CI], 0.41 to 0.77; P=0.001), and the absolute difference was 11.0 percentage points (95% CI, 4.5 to 17.5). The number needed to treat to prevent one death was 8. One man died after surgery in the radical-prostatectomy group. Androgen-deprivation therapy was used in fewer patients who underwent prostatectomy (a difference of 25.0 percentage points; 95% CI, 17.7 to 32.3). The benefit of surgery with respect to death from prostate cancer was largest in men younger than 65 years of age (relative risk, 0.45) and in those with intermediate-risk prostate cancer (relative risk, 0.38). However, radical prostatectomy was associated with a reduced risk of metastases among older men (relative risk, 0.68; P=0.04).
  
  
  CONCLUSIONS
  Extended follow-up confirmed a substantial reduction in mortality after radical prostatectomy; the number needed to treat to prevent one death continued to decrease when the treatment was modified according to age at diagnosis and tumor risk. A large proportion of long-term survivors in the watchful-waiting group have not required any palliative treatment. (Funded by the Swedish Cancer Society and others.).
authors.affiliation: From the Departments of Surgical Sciences (A.B.-A., M.H.) and Immunology, Genetics, and Pathology (C.B.), and the Regional Cancer Center Uppsala Örebro (L.H., H.G.), Uppsala University Hospital, Uppsala, the School of Health and Medical Sciences, Örebro University and Department of Urology, Örebro University Hospital, Örebro (S.-O.A., O.A., J.-E.J.), the Department of Urology, Linköping University Hospital, Linköping (A.S.), the Department of Oncology and Pathology, Division of Clinical Cancer Epidemiology (G.S.), and Department of Medical Epidemiology and Biostatistics (J.P., H.-O.A.), Karolinska Institutet, Stockholm, and the Division of Clinical Cancer Epidemiology, Sahlgrenska Academy, Gothenburg (G.S.) - all in Sweden; King's College London, School of Medicine, Division of Cancer Studies, London (L.H., H.G.); Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School (J.R.R.), and the Department of Epidemiology, Harvard School of Public Health (J.R.R., H.-O.A.) - all in Boston; and the Department of Urology, Helsinki University Central Hospital (K.T.), and the Department of Pathology, University of Helsinki (S.N.) - both in Helsinki.
authors.forename: Anna
authors.initials: A
authors.lastname: Bill-Axelson
authors.forename: Lars
authors.initials: L
authors.lastname: Holmberg
authors.forename: Hans
authors.initials: H
authors.lastname: Garmo
authors.forename: Jennifer R
authors.initials: JR
authors.lastname: Rider
authors.forename: Kimmo
authors.initials: K
authors.lastname: Taari
authors.forename: Christer
authors.initials: C
authors.lastname: Busch
authors.forename: Stig
authors.initials: S
authors.lastname: Nordling
authors.forename: Michael
authors.initials: M
authors.lastname: Häggman
authors.forename: Swen-Olof
authors.initials: SO
authors.lastname: Andersson
authors.forename: Anders
authors.initials: A
authors.lastname: Spångberg
authors.forename: Ove
authors.initials: O
authors.lastname: Andrén
authors.forename: Juni
authors.initials: J
authors.lastname: Palmgren
authors.forename: Gunnar
authors.initials: G
authors.lastname: Steineck
authors.forename: Hans-Olov
authors.initials: HO
authors.lastname: Adami
authors.forename: Jan-Erik
authors.initials: JE
authors.lastname: Johansson
mesh_terms: D000367:Age Factors; D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000517:prevention & control; D010166:Palliative Care; D011468:Prostatectomy / Q000379:methods; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000601:surgery; D012306:Risk; D017741:Survivors; D057832:Watchful Waiting
chemical_list: D000726:Androgen Antagonists